South Korea’s Boryung begins expansion of penicillin facility to boost antibiotic supply

South Korean pharmaceutical manufacturer Boryung has begun construction to expand its oral penicillin antibiotic production facility in Ansan, South Korea. The company said the project will increase the site’s total floor area by more than 50% and more than double annual production capacity once completed.

Boryung said the upgraded facility will incorporate systems aligned with global manufacturing and quality standards. Planned enhancements include digital transformation initiatives such as automated packaging systems and process-innovation technologies intended to reduce operational workload, minimize human error, and improve product consistency.

The company noted that oral penicillin antibiotics were designated national essential treatments by South Korea’s Ministry of Food and Drug Safety in 2023, following supply instability during and after the COVID-19 pandemic. Boryung currently provides more than 60% of domestic contract-manufacturing volume for these products, according to the announcement. 

“This expansion represents a meaningful step forward in elevating the production quality and supply capacity of penicillin antibiotics,” CEO Jay Kim said in a statement. “Boryung will continue to strengthen the stability of the essential treatment supply chain and fulfill its responsibility as a company dedicated to protecting public health.”

_{This piece was created with the assistance of generative AI tools and was edited by our content team for clarity and accuracy.}